Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 12, 2018-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, July 27, 2018 to discuss its second
View HTML
Toggle Summary ImmunoGen Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 21, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the underwriters of its previously announced public offering of common stock have exercised in full
View HTML
Toggle Summary ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 18, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation for its lead
View HTML
Toggle Summary ImmunoGen Announces Closing of Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 11, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common
View HTML
Toggle Summary ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 6, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price
View HTML
Toggle Summary ImmunoGen Announces Proposed Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 5, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at Jefferies 2018 Global Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--May 30, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference.
View HTML
Toggle Summary ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer
Data from Avastin Cohort to be Presented at 2018 ASCO Annual Meeting Updated Data from Carboplatin Dose-Escalation Cohort Demonstrate Increased Response Rate and Durable Benefit with Longer-Term Follow Up Conference Call Scheduled for 8 a.m. ET on Thursday, May 17 WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results
Patient Enrollment in FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine Completed Ahead of Schedule; On Track for Top-Line Results in the First Half of 2019 Encouraging Data Reported from FORWARD II Assessment of Mirvetuximab with Keytruda ® ; Additional Combination Data to be Presented in 2018,
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd Annual Health Care Conference
WALTHAM, Mass. --(BUSINESS WIRE)--May 2, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Deutsche Bank 43 rd Annual Health Care Conference .
View HTML